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ABSTRACT
For over 100 years, the association of eosinophils with 
bronchial asthma has been known. Over the past 20 years, 
the proteins comprising the eosinophil granule have been iso-
lated and characterized. Four proteins are recognized and 
termed the major basic protein (MBP), the eosinophil peroxi-
dase (EPO), the eosinophil-derived neurotoxin (EDN), and the 
eosinophil cationic protein (ECP). The activities of these pro-
teins are reviewed with emphasis on their abilities to interact 
with structures in the bronchus and to reproduce features of the 
pathology of bronchial asthma. In addition, the relationship of 
these proteins to bronchial hyperreactivity, a major stigma of 
bronchial asthma, is discussed, and information highlighting 
the role of MBP is reviewed. Evidence also exists that eosinophil 
granule proteins may interact with the nervous system, and 
results showing increased vagal reactivity in an experimental 
animal model and the role of MBP as an allosteric muscarinic 
M2 receptor are presented. Finally, the effects of eosinophil 
granule proteins as cytostimulants on other cells including 
basophils, mast cells, neutrophils, platelets and alveolar 
macrophages are reviewed. Overall, these results indicate that 
eosinophil granule proteins have many abilities to alter lung 
function in asthma and to reproduce many of the cardinal 
manifestations of this disease.
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INTRODUCTION
Although the eosinophilic leukocytes were first associated with 
bronchial asthma in 1889,1 it has only been over the past two
decades that a detailed knowledge of the composition and 
properties of the eosinophil granule has been achieved.2 The 
hypothesis that the eosinophil is associated with bronchial 
asthma has been reviewed previously.3-5 Information relating 
the eosinophil to bronchial asthma will be reviewed with partic-
ular attention to information supporting a role for eosinophil 
granule cationic proteins in the pathophysiology of bronchial 
asthma.
THE EOSINOPHIL GRANULE AND ITS COMPLEMENT 
OF CATIONIC PROTEINS
The eosinophil contains four predominant cationic molecules 
including the eosinophil peroxidase (EPO), the major basic pro-
tein (MBP), the eosinophil cationic protein (ECP), and the 
eosinophil-derived neurotoxin (EDN). The biochemical proper-
ties of these proteins were recently reviewed in detail2 and are 
summarized briefly.
Major basic protein
MBP is composed of a single polypeptide chain of 117 amino 
acids. MBP is rich in arginine, has a molecular weight of 
approximately 14000, and a calculated isoelectric point of 
10.92 MBP cDNA specifies a pre-promolecule with a 90 amino 
acid pro-sequence followed by the 117 acidic amino acid 
sequence for MBP itself. The pro-portion of the 90 amino acid 
sequence is enriched in acidic amino acids, especially glutamic 
acid, and its calculated isoelectric point is 3.9. ProMBP, consist-
ing of the combination of the pro-portion and MBP itself, is a 
molecule of 270 amino acids with approximately equal num-
bers of strongly basic and acidic amino acids and an isoelectric 
point of 6.2. Recently, proMBP was expressed, purified and par-
tially characterized.6 Interestingly, proMBP lacks the toxic and 
cytostimulatory activities of MBP. In contrast, MBP is a potent 
toxin able to damage various parasites (both helminths and pro-
tozoa), kill bacteria and mammalian cells, cause histamine 
release from basophils and mast cells, and activate neutrophils, 
platelets and eosinophils themselves.' The activities of MBP rel-
evant to bronchial asthma are discussed. MBP is localized to the 
eosinophil granule core.
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Eosinophil cationic protein
ECP is a markedly basic protein, pl 10.8, whose partial N-
terminal amino acid sequence showed marked homology to 
that of EDN and pancreatic ribonuclease.2 Analysis of ECP 
cDNA showed that it codes for a pre-proprotein of 160 amino 
acids and a protein of 133 amino acids with a molecular weight 
of 15600. The ECP amino acid sequence showed 60% identity 
to EDN and 31% to human pancreatic ribonuclease. Therefore, 
ECP is a member of the ribonuclease gene superfamily; other 
members include EDN, pancreatic ribonuclease and human 
angiogenin. ECP is localized to the eosinophil granule matrix; 
its functions include marked toxicity to bacteria, helminths, pro-
tozoa and mammalian cells.
Eosinophil-derived neurotoxin
EDN is so named because it causes a neurotoxic reaction when 
injected into the brains of rabbits and guinea-pigs.2 As indicated 
above, EDN is homologous to pancreatic ribonuclease and is 
also a member of the ribonuclease superfamily. EDN cDNA has 
been cloned and it encodes a polypeptide of 134 amino acids 
with a molecular weight of 15500. Both ECP and EDN are 
localized to chromosome 14 and are present in the eosinophil 
granule matrix. In comparison to the other eosinophil granule 
proteins, which are potent toxins, EDN is only weakly toxic to par-
asites and mammalian cells.
Eosinophil peroxidase
The partial amino acid sequence of EPO has been determined, 
and its cDNA has been cloned (reviewed in 2). ERG cDNA codes 
for a 381 base pair prosequence, a 333 base pair sequence cor-
responding to the ERG light chain, a 1 392 base pair sequence 
corresponding to the EPO heavy chain, and a 452 base pair 
un ranslated 3' region. The heavy and light EPO subunits have 
molecular weights of 12712 and 53011 with isoelectric points of 
10.8 and 10.7, respectively. The EPO sequence is strikingly similar 
to that of myeloperoxidase and thyroid peroxidase; thus, EPO 
belongs to a multigene family that includes these proteins, as well 
as lactoperoxidase.2 EPO is localized to the matrix of the crystalloid 
containing granules. EPO can act as either a cationic toxin in the 
absence of hydrogen peroxide or a peroxidase in the presence of 
hydrogen peroxide. As a peroxidase, the functions of EPO have 
been extensively studied, and it is able to generate hypohalous 
acids, especially hypobromous acid. These oxidants are potent 
effector molecules that are able to kill a variety of targets including 
parasites, bacteria, viruses, mycoplasma and fungi. The properties 
of the eosinophil granule proteins are summarized in Table 1.
EFFECTS OF EOSINOPHIL GRANULE PROTEINS ON 
BRONCHI
Toxicity for respiratory epithelium
Initial experiments indicated that eosinophil granule MBP from 
both guinea-pig and human eosinophils acts directly on the
Table 1. Properties of human eosinophil granule proteins and their encoding cDNA and genes
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airway. For example, a detailed analysis of the effects of MBP on 
guinea-pig respiratory epithelium in vitro demonstrated that
MBP concentrations as low as 10μg/mL produced ciliostasis at
48h Gnd 100μg/mL of MBP slowed ciliary beating within 3h
and ciliary motion ceased within 23 h.8-10 Microscopic examina-
tion showed varying degrees of epithelial damage which was 
directly related to the dose and length of exposure to MBP. At
the lowest concentration of MBP tested,10μg/mL, the epithe-
lium was disrupted and damoged cells were free in he lumen of
the guinea-pig tracheal rings. With higher MBP concentrations
of 50μg/mL ond 100μg/mL, the epithelium wos extensively
damaged. Ciliated and brush cells were detached and individ-
ual cells were destroyed leaving behind only basal cells. Both 
guinea-pig and human MBP had these effects on respiratory 
epithelium, and the levels of MBP in sputum specimens of 
patients with asthma approximated or exceeded those needed 
for biologic activity in vitro.10 Subsequent investigations of the 
activities of eosinophil cationic proteins incubated with guinea-
pig tracheal epithelium revealed that MBP and EPO were active, 
whereas ECP was considerably less potent and EDN failed to 
damage tracheal epithelium.11 Interestingly, EPO damaged res-
piratory epithelium either by itself or in the presence of hydrogen 
peroxide and a halide. These observations were consistent with 
other experiments showing that MBP caused lysis of human 
A549 and rat type II pneumocytes,12 and that the EPO-H2O2-
halide system is particularly effective in causing Iytic injury to 
these cells.13 Interestingly, the same toxic effects of EPO-H2O2-
halide and MBP were seen on human nasal epithelium in vitro.14
Effects on cilia
The initial studies of the effect of MBP on respiratory epithelium 
showed that it abolishes the ciliary activity of respiratory epithe-
lium.8-10 This effect of MBP was subsequently investigated using 
rabbit tracheal rings and analyses of their ciliary beat fre-
quency.15 The results showed that MBP, while reducing the cili-
ary beat frequency, more strikingly abolished the zones of ciliary 
activity in the tracheal ring. Analyses of axonemes showed that 
their beating was completely inhibited after treatment with MBP. 
The MBP effect appeared to be caused by the inhibition of 
ATPase activity in the axonemes.
Effects on epithelial secretion
The effect of MBP on the electrical properties of tracheal tissue 
was studied, utilizing canine tracheal membranes mounted in 
Ussing chambers.16 These results showed that the addition of 
MBP to the mucosal side (but not the submucosal side) of the 
membrane produced an increase in short-circuit current and an 
increase in net chloride secretion; net sodium movement was 
unaffected. Interestingly, other cationic proteins including poly-
arginine, polylysine and histone did not cause significant short-
circuit (or potential) differences; at higher concentrations all of 
these proteins were toxic and caused a marked fall in short-
circuit current and potential differences. These results suggested 
that in patients with acute asthma MBP could contribute to 
abnormalities n airway secretions by stimulating airway epithe-
lial chloride and water secretion.
Vascular permeability
Recently, the effect of eosinophil granule proteins on vascular 
perm ability was analyzed in the hamster cheek pouch.17 
Topical application of MBP at 0.1nmol/L and 0.5nmol/L 
increased the clearance of fluoresceinated dextran (FITC-dx) 
and caused muscle fasciculation and prominent arteriolar 
dilatation. ECP was as potent as MBP. In contrast, topical appli-
cation of EPO was less potent, although when EPO was supple-
mented with H2O2, plasma clearance of FITC-dx was greatly 
increased. Interestingly, neither EPO, EPO+H2O2+halide, ECP 
n r EDN caused muscle fasciculations or arteriolar dilatation. 
Further, the effects on vascular permeability were not mediated 
through histamine because histamine could not be detected in 
perfusate fluids. These results are consistent with a prior study 
that showed that injection of MBP into skin caused a weal-and-
flare reaction.18
EOSINOPHIL GRANULE PROTEINS IN BRONCHIAL 
HYPERREACTIVITY
The above information indicates that eosinophil granule pro-
teins are active on the bronchi and on various components 
of bronchial tissue. These effects can be related to the patho-
physiology of bronchial asthma. A critical facet of bronchial 
asthma is hyperreactivity, which has also been related to 
the eosinophil.5
Relationship of bronchial hyperreactivity and blood 
eosinophilia
Three separate studies have investigated the relationship 
between peripheral blood eosinophilia and bronchial hyper-
reactivity.19-21 These reports came to essentially the same 
conclusion. They demonstrated that the degree of bronchial 
hyperreactivity to histamine or methacholine was inversely 
related to the number of peripheral blood eosinophils. The 
experiments were performed both in individuals with allergic 
asthma and in individuals with non-atopic asthma.21 For exam-
ple, in 23 asthmatic patients (14 were atopic and nine were 
non-atopic) an inverse correlation was found between baseline 
eosinophil count and PC20 (r=-0.71; P<0.001). In atopic sub-
jects, the peripheral blood eosinophil count and the histamine 
PC20 were inversely correlated (r=-0.74; P<0.01). Further-
more, in non-atopic subjects, the peripheral blood eosinophil 
count and histamine release were also inversely related 
(r=-0.68; P<0.05).21 Investigation of the relationship between 
airway reactivity and various atopic factors was conducted using 
met acholine challenge in 87 patients with asthma.20 Whereas
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there were no significant correlations between airway reactivity 
and the threshold of intracutaneous reaction with house dust, 
serum lgE concentration or the level of lgE antibody to mites, a 
significant correlation was found between airway reactivity and 
peripheral blood eosinophil counts.20
Bronchial hyperreactivity and pulmonary 
eosinophilia
Analysis of the relationship between eosinophils in bronchoalve-
olar lavage (BAL) fluids and airway hyperreactivity was made in 
17 patients with mild atopic asthma (nine symptomatic, eight 
asymptomatic) and 14 non-asthmatic control sublects.22 A sig-
nificant difference (P<0.01) was found between the percentage 
of eosinophils in BAL fluids from patients with reactive airways 
(methacholine PC20 less than 4mg/m L) and those without reac-
tive airways (methacholine PC20 greater than 4mg/mL). In addi-
tion, the quantity of MBP recovered in the BAL fluids was lowest 
in non-atopic normal individuals, and increased in patients with 
hay fever, asymptomatic asthma, and symptomatic asthma, the 
latter group having the highest levels (P<0.01 for the difference 
between symptomatic asthma patients and normal individuals, 
and P<0.05 for the difference between symptomatic asthma 
patients and hay fever patients). Further, the levels of MBP 
recovered in the BAL fluids were related to the percentage of 
eosinophils in the BAL fluid (r=+0.64; P<0.001). Lastly, corre-
lations existed between the degree of airway reactivity and MBP 
levels in the BAL fluids (r=-0.59; P<0.01); the percentage of 
eosinophils in the BAL fluids (r=-0.53; P<0.05); and the per-
centage of epithelial cells in the BAL fluids (r=-0.41; P<0.05). 
Overall, these results support the hypothesis that asthma, even 
in its mildest manifestations, as well as non-specific bronchial 
hyperreactivity, is caused by eosinophil-mediated inflammation.
Relationship between BAL eosinophilia and 
bronchial hyperreactivity
Studies of airway reactivity in cynomolgus monkeys showed 
relationships between eosinophils and airway reactivity.23,24 
Utilizing cynomolgus monkeys, the effect of repeated inhalation 
of Ascaris suum extract on airway cellular composition and air-
way responsiveness was tested.25 BAL was conducted, and air-
way responsiveness to methacholine administration was 
measured over a 10 week period; during this period, control 
animals were exposed to vehicle-inhalation challenge and com-
pared with the animals inhaling A. suum extracts. Repeated 
inhalation of A. suum extracts resulted in a prolonged inflam-
matory reaction characterized by a striking increase in airway
eosinophils (from 3±1%to 59±15%; P<0.01). This airway
eosinophilia was associated with an increase in airway respon-
siveness as shown by a leftward shift of the methacholine dose-
response curve, an increase in the slope of the dose-response 
curve and a decrease in the PC100 values (the dose of metha-
choline required to cause a 100% increase in lung resistance).
Eosinophil numbers and MBP concentrations in the BAL fluids 
both correlated with the methacholine PC100 values (r=+0.61; 
P<0.01 and r=+0.64; P<0.01, respectively). Lung biopsy 
specimens taken from these animals at week 10 showed a strik-
ing eosinophil infiltration in the antigen-challenged animals. 
Inspection of these results showed that at week 2 there was no 
increased responsiveness to methacholine, although striking 
BAL eosinophilia was evident, and the level of BAL fluid MBP 
was not significantly different from control values. In contrast, at 
week 4, bronchial hyperreactivity increased dramatically, maxi-
mal BAL fluid eosinophila was present, and MBP levels in the 
BAL fluids were maximal. These results suggest that the number 
of BAL eosinophils is not as critical as the level of BAL MBP, and 
this suggests that the release of toxic eosinophil granule proteins 
may be a better correlate of bronchial hyperreactivity than the 
number of eosinophils per se.25
Provocation of bronchial hyperreactivity by cationic 
molecules
As summarized above, MBP levels were related to bronchial 
hyperreactivity in humans and monkeys, suggesting that MBP 
itself ight cause hyperreactivity. This hypothesis was tested by 
directly administering purified eosinophil granule proteins and 
measuring their effects on pulmonary function and airway 
responsiveness in primates.26 In these experiments, MBP, EPO, 
ECP and EDN were directly instilled into the monkey's trachea. 
The effects of instillation on both respiratory resistance and air-
way reactivity were measured. Within 5 min, the administration 
of MBP and EPO caused a significant increase in airway resis-
tance which decreased to baseline levels by 60min. In a ran-
domized cross-over study design in five animals, the effect of 
direct instillation of purified granule proteins on airway respon-
siveness was compared with the effect of column buffer instilla-
tion. MBP instillation resulted in a dose-related decrease in PC100 
values for each animal (Table 2). The mean change in log PC100
values for 0.50mg and 1.0mg MBP were -0.39±13 and
-1 .02±0.36, respectively. MBP-induced increases in oirwoy
responsiveness were shown by a parallel shift in the cumulative 
methacholine dose-response curves (Fig. 1), and only MBP 
caused a significant change in the log methacholine PC100 val-
ues. Surprisingly (because of its marked biologic activity), EPO 
did not cause such changes although 2.0mg were administered 
in an effort to seek a dose-response relationship between EPO 
administration and airway reactivity. Further, administration of 
EPO+H2O2+KI was not associated with a change in airway 
reactivity. These results suggest that MBP has an effector role on 
the pathogenesis of airway responsiveness and that this may 
involve interaction ith resident airway tissue cells.26 
In c tinuing studies of the ability of MBP and cationic pro-
teins to alter airway hyperresponsiveness, a rat model has been 
em loyed in which cationic proteins were directly instilled into 
the trachea, and the response to inhaled methacholine was 
determined.27 MBP caused a marked immediate increase in
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Table 2. Effects of eosinophil granule proteins on airway 
responsiveness
airway responsiveness to inhaled methacholine, which had sub-
sided by 48h. Poly-L-arginine and poly-L-lysine also increased 
methacholine sensitivity; acetylation of the charged groups on 
poly-L-lysine abolished this effect. Histologic examination of the 
airways failed to reveal epithelial shedding 1h after MBP or 
polycation instillation. These results suggest that airway instilla-
tion of MBP causes a short-lived increase in airway responsive-
ness, that the high density of surface cationic charge of MBP 
may be responsible for this effect, and, finally, that airway 
epithelial shedding is not a necessary prerequisite for the effect. 
Subsequently, the effects of a series of cationic proteins are 
investigated including MBP, platelet factor 4 (PF4) and cathep-
sin G.28 All of these proteins induced a two- to three-fold 
increase in airway responsiveness 1h after instillation, and 
admixing these cationic proteins with heparin inhibited the 
development of bronchial hyperreactivity. Similar results were 
obtained with poly-L-lysine. 
 The mechanism of the MBP effect was further studied, utilizing 
poly-L-lysine as the agonist.29 In these experiments, poly-L-lysine 
induced a five-fold increase in airway responsiveness, and this 
was inhibited by a neonatal capsaicin treatment and potentiated 
by phosphoramidion. Further, pretreatment with a selective NK-
1 receptor antagonist inhibited the poly-L-lysine-induced airway 
responsiveness in plasma protein extravasation. These results 
demonstrate that cationic proteins can activate C-fibers in the 
airways and suggest a link between inflammatory cell accumu-
lation and sensory nerve activation. Finally, the effect of MBP 
and synthetic polycations on the induction of airway respon-
siveness has recently been attributed to the generation of 
bradykinin.30 In these experiments, BAL was performed after 
intratracheal instillation of MBP or poly-L-lysine, and the levels 
of kinins and kallikrein-like activity were determined. Both MBP 
and poly-L-lysine induced a three- and eight-fold increase in the 
levels of kallikrein-like activity in immunoreactive kinins, respec-
tively. Analyses of dose-response curves to methacholine before
Fig. 1 Methacholine concentration-response curve from an adult male 
cynomolgus monkey that received an intratracheal instillation of 1.0mg 
MBP. The administration of column buffer had no effect on airway 
responsiveness. Rrs is a measure of respiratory system impedance 
derived from forced oscillations superimposed on tidal breathing. 
(Figure has been modified and used with permission from Gundel RH, 
Lefts LG and Gleich GJ. J. Clin. Invest. 1991; 87: 1470-3).26
and after MBP or poly-L-lysine instillation showed an increase in 
airway responsiveness which was inhibited by pretreatment with 
a selective bradykinin-2 receptor antagonist (NPC 17713). 
These results suggest that MBP and poly-L-lysine activate 
kallikrein and stimulate the generation of immunoreactive kinins 
in vivo and that this effect is related to the cationic charge of 
these proteins. Thus, these results suggest that following MBP 
instill tion the increase in airway responsiveness is due to the 
generation of kinin activity. 
 Another series of experiments explored the ability of 
eosinophil granule proteins to cause hyperreactivity of respira-
tory smooth muscle in vitro.31 Rings of guinea-pig trachea, some 
with the epithelium gently removed by rubbing, were incubated 
in buffer or with human MBP. The tracheal rings were then 
tested for their reactivity to acetylcholine and histamine. MBP 
did not affect the reactivity of rings in which epithelium had been 
removed, but it significantly augmented that of unrubbed rings 
to acetylcholine and histamine. These results suggest that MBP 
interacts with epithelium and indirectly caused increased reac-
tivity in respiratory smooth muscle.31 The influence of epithelial 
r moval on the effects of MBP on hyperreactivity was subse-
quently explored in a series of experiments utilizing an in vivo 
in situ tracheal preparation from which the epithelium could 
be excised. The first experiments, conducted in dogs, showed 
that the response to intro-arterial acetylcholine was augmented 
substantially in animals receiving MBP by intra-epithelial instil-
lation.32 In contrast, instillation of MBP directly into the subep-
ithelial tracheal smooth muscle did not alter contractility. 
Essentially the same experiments were then performed in 
guinea-pigs, and here direct application of MBP to the respira-
tory pithelium caused active force generation within 1m of 
pithelial contact with MBP.33 MBP denatured by boiling did not
40 GJGLEICH
elicit active tension. MBP also caused augmented contraction to 
intravenous acetylcholine. These results indicate that MBP 
causes direct contraction of airway smooth muscle in an epithe-
lial-dependent manner, and an increase in responsiveness to 
acetylcholine (presumably analogous to bronchial hyperreactiv-
ity). Finally, the ability of MBP to cause contraction of guinea-
pig trachealis muscle is blocked by atropine, whereas 
contraction of guinea-pig trachealis muscle in response to 
either polylysine or polyarginine is not affected by atropine pre-
treatment.34 In contrast, tracheal smooth muscle contraction 
elicited by either MBP or polylysine is blocked by pretreatment 
with indomethacin. These results suggest that MBP-induced 
muscle contraction is mediated through both stimulation of the 
parasympathetic nervous system and secretion of a product of 
the cyclooxygenase pathway, while neither polylysine nor poly-
arginine causes tracheal smooth muscle contraction via the 
parasympathetic nervous system. This suggests that the cationic 
charge of MBP is not solely responsible for its effect on tracheal 
smooth muscle in the guinea-pig.34
EOSINOPHIL GRANULE PROTEINS AND VAGAL 
FUNCTION
Evidence for decreased lung muscarinic M2 receptor 
function in sensitized animals
Because excitatory functional potentials elicited by vagal stimula-
tion are increased, antigen inhalation in guinea-pigs is associ-
ated with increased release of acetylcholine from vagus nerves.35 
In the lung, acetylcholine release from the vagus nerves is under 
the control of inhibitory receptors on postganglionic nerves.36 
Inhibitory receptors are classified as muscarinic M2 receptors and 
the muscarinic receptors on airway smooth muscles are class-
ified as muscarinic M3 receptors.37 Thus, as shown in Fig. 2, 
acetylcholine released from the vagus nerve stimulates both 
muscarinic M3 receptors on airway smooth muscle causing con-
traction and muscarinic M2 receptors on nerves decreasing fur-
ther release of acetylcholine. The negative feedback control of 
acetylcholine on the neuronal M2 receptors can be blocked by 
gallamine which potentiates vagally induced bronchoconstric-
tion as much as ten-fold.39 In an opposite manner, pilocarpine, 
which stimulates M2 receptors, decreases vagally induced bron-
chospasm.36 Yet, other experiments have shown that the function 
of the M2 inhibitory receptors is impaired following antigen chal-
lenge of sensitized animals.39,40 Because positively charged mol-
ecules, such as polyarginine, polylysine, basic histones and 
protamine, are antagonists for the M2 receptor,41 the possibility 
that negatively charged substances, such as heparin and polyg-
lutamate, which are able to neutralize the effects of MBP,9,42,43 
might reverse M2 receptor function was tested. Guinea-pigs were 
anesthetized, tracheotomized, vagotomized, paralyzed and ven-
tilated.40 Stimulation of the vagus nerves of these animals caused 
bronchoconstriction and bradycardia, and in control animals,
Fig. 2 In the airways, release of acetycholine from the vagus nerve 
contracts smooth muscle by stimulating muscarinic M3 receptors. At the 
same time, the acetylcholine feeds back onto inhibitory muscarinic M2 
receptorss on the nerve nedings, and thereby limits further release of 
acetylcholine. (Used with permission from Jacoby DB, Gleich GJ and 
Fryer AD. J. Clin. Invest. 1993; 91: 1314-18).38
pilocarpine attenuated vagally induced bronchoconstriction by 
stimulating neuronal muscarinic M2 receptors. Conversely, block-
ade of these receptors by gallamine potentiated vagally induced 
bronchospasm. In contrast, in the sensitized and challenged ani-
mals, the effects of both drugs were markedly reduced in keep-
ing with the hypothesis that the function of the M2 receptor was 
impaired. Intravenous administration of heparin or polyglutamic 
acid restored the effects of both pilocarpine and gallamine on 
vagally induced bronchospasm, indicating a recovery of M2 
r c ptor function. 
 Thus, these experiments suggested that a polycationic sub-
stance, such as MBP, EPO or ECP, might be responsible for the 
antigen-induced pulmonary M2 receptor dysfunction. This 
hypothesis was directly tested by analyzing the ability of puri-
fied eosinophil granule proteins to bind to M2 and M3 recep-
tors.38 MBP inhibited the binding of N-[3H]methylscopolamine to 
M2 receptors, but not to M3 receptors; MBP also inhibited the 
atropine-induced association of the N-[3H]methylscopolamine 
receptor complexes in a dose-dependent fashion, showing 
that the interaction of MBP with the M2 receptor is allosteric. 
These results suggest that MBP functions as an endogenous 
llosteric inhibitor of antagonist binding to the muscarinic M2 
receptor.
 Rece t experiments have tested whether eosinophils are criti-
cal for production of the muscarinic M2 receptor blockade by 
inhibiting tissue eosinophilia using an antibody to interleukin 
(IL)-5.44 These results indicate that pretreatment of guinea-pigs 
with the monoclonal antibody to IL-5, TRFK-5, causes a loss of 
the muscarinic M2 receptor blockade induced by sensitization. 
Further, the pretreatment with TRFK-5 selectively inhibited the 
migration of eosinophils into the lungs, as measured by lung 
lavag , suggesting that the function of muscarinic M2 receptors 
in ntigen-challenged guinea-pigs can be protected by inhibit-
ing eosinophil influx into the lungs.
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EFFECTS OF EOSINOPHIL GRANULE PROTEINS ON 
OTHER CELLS
Effects on basophils and mast cells
Because basophils, mast cells and eosinophils coexist in 
bronchial asthma, the hypothesis that the eosinophil granule 
protein might activate these cells was tested.45 Incubation of 
MBP with blood cells enriched in basophils indicated that MBP 
caused a dose-related increase in histamine release which 
reached a maximum by 1h and was calcium-, energy- and tem-
perature-dependent.46 Purified rat mast cells behaved in a simi-
lar fashion, although, in this case, histamine release was largely 
complete by 1 min. Thus, MBP causes a non-cytolytic histamine 
release from leukocytes; it can activate both mast cells and 
basophils. Subsequently, the other granule proteins were tested 
for their abilities to activate basophils and rat mast cells and 
cause histamine release. In the case of basophils, only MBP 
caused leukocyte histamine release, whereas with rat peritoneal 
mast cells, both MBP and ECP were active.46 Analyses of the 
responsiveness of leukocytes from individual selected donors 
revealed a considerable range of responsiveness to MBP from 
baseline levels of approximately 5% histamine release to 
responses of over 50% histamine release.47 Interestingly in this 
study, leukocytes of atopic individuals could not be distin-
guished from leukocytes of non-atopic individuals in their 
response to MBP. As mentioned previously, the MBP stimulated 
histamine release from basophils was calcium-, energy- and 
temperature-dependent45 and was blocked by a calmodulin 
antogonist and by theophylline and partially inhibited by an 
inhibitor of phospholipase A2.48 Interestingly, the MBP-stimu-
lated histamine release was unaffected by inhibition of protein 
kinase C, whereas pretreatment with pertussis toxin caused a 
concentration-dependent inhibition of histamine release.
 Recently, the abilities of cytokines to potentiate basophil acti-
vation by eosinophil granule MBP were tested.49 Preincubation 
of basophils and mononuclear cells with IL-3 or IL-5 caused a 
concentration-dependent enhancement of MBP-dependent his-
tamine release. Preincubation with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) similarly enhanced MBP-
induced histamine release. Cytokine incubation both reduced 
the MBP concentrations required for histamine release and 
enhanced the rate of MBP-induced histamine release. MBP also 
stimulated low levels of leukotriene (LT)C4 release from purified 
basophils, 84-99% purity, and the MBP-stimulated LTC4 release 
was also potentiated by preincubation with IL-3, IL-5 and GM-
CSF. These results indicate that IL-3, IL-5 and GM-CSF may 
contribute to the pathogenesis of allergic and other disorders 
characterized by eosinophilia, not only by activation of 
eosinophils, but also by potentiation of basophil mediator 
release stimulated by MBP.49
 The granules of mast cells bind EPO, and the resulting gran-
ule-EPO complexes catalyze the iodination of proteins in killing
of microorganisms.50 The EPO-H2O2-l- system also induces rat 
cell degranulation and histamine release.51 Whereas EPO-
H2O2-l- was non-cytotoxic at low EPO concentrations, at higher 
concentrations ultrastructural evidence of mast cell damage was 
apparent. Interestingly, the EPO-mast-cell granule complex is 
more effective than free EPO for stimulating mast cell secretion. 
  Finally, recent experiments tested eosinophil granule pro-
teins for their ability to induce histamine release from human 
skin mast cells.52 The four cationic proteins over a concentration
range of 10-200μg/mL did not induce significant histamine
release nor did they prime anti-IgE-induced histamine release 
from human skin mast cells significantly. However, incubation of 
MBP and EPO with the mast cells significantly inhibited hista-
mine release that was induced by substance P and by com-
pound 48/80TM. Thus, these results suggest that skin mast cells, 
unlike rat peritoneal mast cells, are not stimulated by eosinophil 
granule proteins.
Effects on neutrophils
Neutrophils and eosinophils are commonly present in certain 
allergic reactions, particularly late phase reactions in the skin.53 
Therefore, the effect of MBP on neutrophils has also been 
tested.54 Incubation of neutrophils with MBP produced a con-
centration-dependent chemiluminescence response that 
peaked after 50-70min; ECP and EDN did not induce chemilu-
minescence. The MBP-induced chemiluminescence was abol-
ished in the absence of calcium and was absent in neutrophils 
isolated from two individuals with chronic granulomatous dis-
ease. MBP also stimulated the release of superoxide anion and
lysozyme, but not β-glucuronidase or lactate dehydrogenase.
MBP and platelet-activating factor (PAF) were synergistic in their 
ability to cause superoxide release. These results indicate that 
MBP activates neutrophils in a non-cytolytic fashion and points 
to an interaction between these cells, particularly in allergic late 
phase reactions.
 Comparison of the activity of MBP on basophils and neutro-
phils has shown that although both basophils and neutrophils 
are activated by MBP and have many characteristics in com-
mon, they differ in calcium signaling and sensitivity to priming 
by cytokines.55 Activation of neutrophil superoxide anion release 
by MBP proceeds independently of an elevation in calcium and 
is not enhanced by exposure of neutrophils to GM-CSF. In con-
trast, an elevation in calcium appears to be integral to basophil 
activation by MBP. Further, as mentioned previously, basophil 
mediator release stimulated by MBP is enhanced by IL-3, IL-5 
and GM-CSF.50
Effects on platelets
Platelets are known to be involved in bronchial asthma and, 
thus, form a reasonable target for stimulation by eosinophil 
granule proteins.56,57 Analyses of the activities of eosinophil
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granule proteins on purified platelets revealed that both MBP 
and EPO evoke a dose-dependent non-lytic secretion of platelet 
5-hydroxytryptamine in unstirred platelet suspensions even in 
the presence of indomethacin.58 MBP also caused secretion of
platelet-α granule and lysosome components. The platelet
secretion caused by MBP and EPO was inhibited by PGE1, but 
the nature of the inhibition differed from that of thrombin. 
Furthermore, secretion mediated by EPO was not due to its 
enzymatic activity because EPO promoted secretion in the 
absence of H2O2 and in the presence of sufficient catalase to 
degrade any endogenously produced hydrogen peroxide. 
Finally, heparin, which has no effect on the catalytic activity of
EPO, inhibited EPO-dependent secretion presumably by bind-
ing to EPO. These results differ from prior information where the
EPO-mediated mast cell secretion was absolutely dependent on
the enzymatic activity of EPO and required exogenously added 
hydrogen peroxide and halide.51 Thus, these results suggest that 
MBP and EPO can be classified as strong platelet active ago-
nists with a distinctive mechanism of action.
Effects on mucous secreting cells
Because one of the prominent features of an asthma attack is 
hypersecretion of mucous from the airway mucosa, the effect of 
eosinophil granule proteins on mucous secretion has been 
tested.59 Eosinophil lysates and crude extracts from isolated 
eosinophil granules both caused dose-dependent release of 
respiratory glycoconjugates from cultured feline tracheal 
explants. MBP, ECP and EDN were purified and tested for their 
activities, and ECP caused a dose-dependent increase in respira-
tory glycoconjugates from both feline and human airway explants 
and also stimulated the release of the serous cell-marker, lacto-
ferrin, from human bronchial explants. EDN failed to affect respi-
ratory glycoconjugate release, whereas MBP inhibited release 
from feline explants. Thus, these results suggest that ECP stimu-
lates mucous release and lactoferrin release, whereas MBP 
inhibits mucous release.
Effects of eosinophil granule proteins on 
eosinophils themselves
Recent experiments indicate that MBP and EPO at concentra-
tions easily achieved in vivo induce eosinophil degranulation as 
measured by release of EDN; in contrast, ECP was inactive.7 
MBP and EPO induced EDN release comparable to one of the 
strongest agonists for eosinophils, namely secretory lgA (slgA). 
Interestingly, degranulation of eosinophils induced by MBP was 
only partially dependent on calcium and no elevation of intra-
cellular calcium concentration was observed in MBP-stimulated 
eosinophils. MBP also stimulated the production of IL-8, up to 
eightfold, by eosinophils in a dose-dependent manner; the 
expression of IL-8 mRNA by eosinophils was confirmed by the 
reverse transcription-polymerase chain reaction.6 Thus, MBP
and EPO may act as autocrine mediators in the pathogenesis of 
eosinophil-associated diseases, such as bronchial asthma, by 
creating a vicious cycle of eosinophil infiltration, eosinophil 
degranulation and continued eosinophil activation by MBP and 
EPO.
Effects on lung macrophages
Because MBP is released into pulmonary secretions in patients 
with asthma, the effects of MBP on superoxide anion release 
from alveolar macrophages have been analyzed.60 Guinea-pig 
alveolar macrophages were harvested and incubated with MBP, 
and the macrophages were stimulated with phorbol myristate 
acetate (PMA); an i mediate reduction in superoxide release 
from the alveolar macrophages was observed. Similarly, in 
macrophages incubated with MBP for 48h a significant reduc-
tion was observed in PMA-induced superoxide anion release. 
While the immediate MBP effect on superoxide anion release 
was not due to cytotoxicity, the late effect at 48h was due to a 
direct toxic effect of MBP on the alveolar macrophages. These 
results suggest that MBP can adversely affect macrophage func-
tion, and that this effect is, in part, due to the cytotoxic effects of 
MBP.
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